Sundar PichaiSundar Pichai earned $164M in 2023

Jeffrey B. Kindler has been a significant player at Pfizer, one of the world’s largest pharmaceutical companies. He started as Senior Vice President and General Counsel in 2002 and quickly climbed the ranks to become CEO in 2006. His legal...

Quick Links
P

Jeffrey B. Kindler

Ex-CEO of Pfizer

Education

B.A. degree, summa cum laude, from Tufts University in 1977 and J.D. degree, magna cum laude, from Harvard Law School in 1980.

Field of Expertise

Legal & Compliance - Law

Sector of Economy

Healthcare

Born

May 13, 1955 - 69 years ago

CEO of Pfizer for

4 years 4 months (Jul 2006 - Dec 2010)

Previous Experience

Chairman and CEO of Boston Market Corporation, President of Partner Brands, Executive Vice President, Corporate Relations and General Counsel of McDonald's Corporation.

Holdings

See how much did Jeffrey B. Kindler make over time.

During his time at Pfizer, Jeffrey B. Kindler had a notable portfolio. When looking at his wealth tied to Pfizer, he commanded significant holdings, particularly around 2010 when his wealth peaked alongside the company's performance. He had around 587,041 shares...

No data yet.

No data yet.

Insider Trading

See recent insider trades of Jeffrey B. Kindler.

No insider trades found for this CEO.

Compensation History

See how much did Jeffrey B. Kindler make over time.

Jeffrey B. Kindler had a varied compensation structure that highlighted his role at Pfizer. His compensation peaked in 2010 with a total of $10.4 million, which included a salary of $1.8 million, a bonus of $3.25 million based on performance metrics, and vested stock options worth about $6.3 million. This compensation was closely tied to the company's financial performance and was linked to specific targets like revenue and earnings per share. Despite earning millions, Kindler faced challenges during his tenure, especially related to the changing landscape of pharmaceuticals. His compensation reflected both the high-stakes nature of leading a major corporation and Pfizer’s philosophy of tying executive pay to performance. After significant changes at the helm, he retired in December 2010, leaving a noteworthy compensation legacy that echoed his contributions to the company.

Year

2010

Total Compensation

$11.82M

Salary

$1.80M

Board Justification

The compensation philosophy aims to align executive compensation with company performance and shareholder interests, targeting the median compensation of peer companies.

Bonus

$3.25M

Board Justification

The bonus was determined based on performance metrics and paid at 120% of the target level award.

Other

$451.08K

Board Justification

Includes severance payment and accrued vacation pay.

Restricted Stock

$6.31M(377.59K RSU)

Board Justification

The RSUs vested upon retirement and were settled in shares of Pfizer stock.

Performance Metrics

The performance metrics included Total Revenue, Adjusted Diluted EPS, and Cash Flow from Operations.

Other Pfizer CEOs

Here are other CEOs of Pfizer